Mateusz Jacek Spałek1, Jan Poleszczuk2,3, Anna Małgorzata Czarnecka1,4, Monika Dudzisz-Śledź1, Aleksandra Napieralska5, Jacek Matysiakiewicz6, Marzanna Chojnacka7, Anna Raciborska8, Aleksandra Sztuder9, Adam Maciejczyk9,10, Agata Szulc9, Tomasz Skóra11, Bożena Cybulska-Stopa12, Tomasz Winiecki13, Joanna Kaźmierska13,14, Bartłomiej Tomasik15,16,17, Jacek Fijuth15, Piotr Rutkowski1. 1. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. 2. Department for Computational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-034 Warsaw, Poland. 3. Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, 02-109 Warsaw, Poland. 4. Mossakowski Medical Research Centre, Department of Experimental Pharmacology, Polish Academy of Sciences, 02-106 Warsaw, Poland. 5. Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland. 6. Trauma and Orthopedic Surgery Department, IXth Ward of the District Hospital of Orthopedics and Trauma Surgery in Piekary Slaskie, 41-940 Piekary Slaskie, Poland. 7. Department of Oncology and Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, 02-034 Warsaw, Poland. 8. Department of Oncology and Surgical Oncology for Children and Youth, Institute of Mother and Child, 01-211 Warsaw, Poland. 9. Department of Radiotherapy, Lower Silesian Oncology Centre, 53-413 Wroclaw, Poland. 10. Department of Oncology, Faculty of Medicine, Wroclaw Medical University, 50-367 Wrocław, Poland. 11. Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków Branch, 31-115 Kraków, Poland. 12. Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 31-115 Kraków, Poland. 13. Radiotherapy Department II, Greater Poland Cancer Centre, 61-866 Poznan, Poland. 14. Electroradiology Department, University of Medical Sciences, 61-701 Poznan, Poland. 15. Department of Radiotherapy, Medical University of Lodz, 92-215 Lodz, Poland. 16. Department of Biostatistics and Translational Medicine, Medical University of Lodz, 95-513 Lodz, Poland. 17. Postgraduate School of Molecular Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Abstract
BACKGROUND: Due to the rarity of osteosarcoma and limited indications for radiotherapy (RT), data on RT for this tumor are scarce. This study aimed to investigate the utilization of RT for osteosarcomas in the recent 20 years and to identify factors related to patients' response to radiation. METHODS: We performed a retrospective analysis of patients irradiated for osteosarcoma treatment. We planned to assess differences in the utilization of RT between the periods of 2000-2010 and 2011-2020, identify the risk factors associated with local progression (LP), determine whether RT-related parameters are associated with LP, and calculate patients' survival. RESULTS: A total of 126 patients with osteosarcoma who received 181 RT treatments were identified. We found a difference in RT techniques between RT performed in the years 2000-2010 and that performed in the years 2011-2020. LP was observed after 37 (20.4%) RT treatments. Intent of RT, distant metastases, and concomitant systemic treatment affected the risk of LP. Five-year overall survival was 33% (95% confidence interval (26%-43%)). CONCLUSIONS: RT for osteosarcoma treatment has evolved from simple two-dimensional palliative irradiation into more conformal RT applied for new indications including oligometastatic and oligoprogressive disease. RT may be a valuable treatment modality for selected patients with osteosarcoma.
BACKGROUND: Due to the rarity of osteosarcoma and limited indications for radiotherapy (RT), data on RT for this tumor are scarce. This study aimed to investigate the utilization of RT for osteosarcomas in the recent 20 years and to identify factors related to patients' response to radiation. METHODS: We performed a retrospective analysis of patients irradiated for osteosarcoma treatment. We planned to assess differences in the utilization of RT between the periods of 2000-2010 and 2011-2020, identify the risk factors associated with local progression (LP), determine whether RT-related parameters are associated with LP, and calculate patients' survival. RESULTS: A total of 126 patients with osteosarcoma who received 181 RT treatments were identified. We found a difference in RT techniques between RT performed in the years 2000-2010 and that performed in the years 2011-2020. LP was observed after 37 (20.4%) RT treatments. Intent of RT, distant metastases, and concomitant systemic treatment affected the risk of LP. Five-year overall survival was 33% (95% confidence interval (26%-43%)). CONCLUSIONS: RT for osteosarcoma treatment has evolved from simple two-dimensional palliative irradiation into more conformal RT applied for new indications including oligometastatic and oligoprogressive disease. RT may be a valuable treatment modality for selected patients with osteosarcoma.
Entities:
Keywords:
bone cancer; image-guided; intensity-modulated; osteosarcoma; radiotherapy; sarcoma
Authors: P G Casali; S Bielack; N Abecassis; H T Aro; S Bauer; R Biagini; S Bonvalot; I Boukovinas; J V M G Bovee; B Brennan; T Brodowicz; J M Broto; L Brugières; A Buonadonna; E De Álava; A P Dei Tos; X G Del Muro; P Dileo; C Dhooge; M Eriksson; F Fagioli; A Fedenko; V Ferraresi; A Ferrari; S Ferrari; A M Frezza; N Gaspar; S Gasperoni; H Gelderblom; T Gil; G Grignani; A Gronchi; R L Haas; B Hassan; S Hecker-Nolting; P Hohenberger; R Issels; H Joensuu; R L Jones; I Judson; P Jutte; S Kaal; L Kager; B Kasper; K Kopeckova; D A Krákorová; R Ladenstein; A Le Cesne; I Lugowska; O Merimsky; M Montemurro; B Morland; M A Pantaleo; R Piana; P Picci; S Piperno-Neumann; A L Pousa; P Reichardt; M H Robinson; P Rutkowski; A A Safwat; P Schöffski; S Sleijfer; S Stacchiotti; S J Strauss; K Sundby Hall; M Unk; F Van Coevorden; W T A van der Graaf; J Whelan; E Wardelmann; O Zaikova; J Y Blay Journal: Ann Oncol Date: 2018-10-01 Impact factor: 32.976
Authors: Thomas F DeLaney; Lily Park; Saveli I Goldberg; Eugen B Hug; Norbert J Liebsch; John E Munzenrider; Herman D Suit Journal: Int J Radiat Oncol Biol Phys Date: 2005-02-01 Impact factor: 7.038
Authors: Gennady N Machak; Sergey I Tkachev; Yuriy N Solovyev; Pavel A Sinyukov; Stanislav M Ivanov; Natalya V Kochergina; Alexey D Ryjkov; Valery V Tepliakov; Benjamin Y Bokhian; Valeria V Glebovskaya Journal: Mayo Clin Proc Date: 2003-02 Impact factor: 7.616
Authors: Patrick Hundsdoerfer; Marion Albrecht; Ursula Rühl; Rüdiger Fengler; Andreas E Kulozik; Günter Henze Journal: Eur J Cancer Date: 2009-09 Impact factor: 9.162